Laver J, Abboud M, Gasparetto C, Gillio A, Smith C, O'Reilly R J, Moore M A
Bone Marrow Transplantation Service, Memorial Sloan-Kettering Cancer Center, New York.
Biotherapy. 1989;1(4):293-300. doi: 10.1007/BF02171005.
Recently it has been recognized that IL-1 plays an important role in hematopoietic regulation. Administration of 5-fluorouracil (5-FU) to mice causes prolonged neutropenia. rHIL-1 injected to mice after 5-FU, accelerated the recovery of hematopoietic progenitors and blood neutrophils. The combination of rhIL-1 and rhG-CSF reduced the neutropenic period significantly. Sublethal irradiation of mice induced profound neutropenia for 3 weeks which was associated with 80% mortality. Administration of rhIL-1 20 hours prior to or 2 hours post irradiation resulted in a significantly improved survival and rapid recovery of the neutrophil count. IL-1 administered alone or in combination with other colony stimulating factors to spontaneous breast tumor bearing mice following 5-FU therapy resulted in a rapid recovery of neutrophils, improved survival, and markedly reduced the tumor mass. Experiments in primates demonstrated that rhIL-1 administered to 5-FU treated animals shortened the neutropenic period from 30 to 17 days and increased the number of marrow progenitors responsive to other CSFs. Prolonged administration of IL-1 (14 days) to these animals resulted in a delayed neutrophil recovery as compared to animals receiving short courses of IL-1. rhIL-1 administered to primates receiving marrow grafts after lethal irradiation, did not result in rapid hematopoietic recovery. In humans, studies with CD-34 positive marrow cells showed that IL-1 had a radioprotective effect on a committed and early marrow progenitors. These data show the therapeutic potential of IL-1 in the treatment of chemoradiotherapy induced myelosuppression.
最近人们认识到,白细胞介素-1(IL-1)在造血调节中发挥着重要作用。给小鼠注射5-氟尿嘧啶(5-FU)会导致长时间的中性粒细胞减少。在5-FU给药后给小鼠注射重组人白细胞介素-1(rHIL-1),可加速造血祖细胞和血液中性粒细胞的恢复。重组人白细胞介素-1(rhIL-1)与重组人粒细胞集落刺激因子(rhG-CSF)联合使用可显著缩短中性粒细胞减少期。对小鼠进行亚致死剂量照射会导致持续3周的严重中性粒细胞减少,这与80%的死亡率相关。在照射前20小时或照射后2小时给予rhIL-1,可显著提高生存率,并使中性粒细胞计数迅速恢复。在5-FU治疗后,单独或与其他集落刺激因子联合给自发乳腺肿瘤小鼠施用IL-1,可导致中性粒细胞迅速恢复、生存率提高,并显著减小肿瘤体积。在灵长类动物身上进行的实验表明,给接受5-FU治疗的动物施用rhIL-1可将中性粒细胞减少期从30天缩短至17天,并增加对其他集落刺激因子有反应的骨髓祖细胞数量。与接受短期rhIL-1治疗的动物相比,对这些动物长期施用IL-1(14天)会导致中性粒细胞恢复延迟。给接受致死剂量照射后接受骨髓移植的灵长类动物施用rhIL-1,并未导致造血迅速恢复。在人类中,对CD-34阳性骨髓细胞的研究表明,IL-1对定向和早期骨髓祖细胞具有辐射保护作用。这些数据显示了IL-1在治疗放化疗引起的骨髓抑制方面的治疗潜力。